Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.36 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.34 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.33 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29673477 | 1.00 | ALDH1A1 (0.37) | ALDH1A1RXFP1L3MBTL1TRPV4MCOLN3 | |
| SCHEMBL7106886 | 0.84 | GAA (0.38) | ALDH1A1RXFP1L3MBTL1MCOLN3KMT2A | |
| SCHEMBL28650941 | 0.83 | HSD11B1 (0.40) | ALDH1A1RXFP1L3MBTL1MCOLN3KMT2A | |
| SCHEMBL20485803 | 0.81 | PTGES2 (0.44) | ALDH1A1KMT2ALMNAPTGES2 | |
| SCHEMBL4313799 | 0.81 | MYC (0.43) | ALDH1A1RXFP1L3MBTL1MCOLN3KMT2A | |
| SCHEMBL30681723 | 0.80 | KMT2A (0.45) | ALDH1A1RXFP1L3MBTL1TRPV4KMT2A | |
| SCHEMBL691798 | 0.80 | KMT2A (0.45) | ALDH1A1RXFP1L3MBTL1TRPV4KMT2A | |
| SCHEMBL30950298 | 0.79 | ALDH1A1 (0.44) | ALDH1A1RXFP1L3MBTL1KMT2ALMNA | |
| SCHEMBL4439 | 0.79 | ALDH1A1 (0.44) | ALDH1A1RXFP1L3MBTL1KMT2ALMNA | |
| SCHEMBL24336054 | 0.79 | KEAP1 (0.36) | ALDH1A1RXFP1L3MBTL1MCOLN3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117177975-B | Pyrimido [5,4, D ] pyrimidine compounds, compositions comprising the same and uses thereof | 蒙特利尔大学 | 2026-05-19 | — | — | CN | disclosed |
| EP-4695235-A1 | NOVEL GSPT1 DEGRADER AND USE THEREOF | Cyrus Therapeutics Inc. (KR) | 2026-02-18 | — | — | EP | disclosed |
| US-12479842-B2 | Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease | UNIVERSITE DE MONTREAL (CA) | 2025-11-25 | — | — | US | disclosed |
| US-12479818-B2 | Treatment of fibrosis with IRE1 small molecule inhibitors | CORNELL UNIVERSITY (US) | 2025-11-25 | — | — | US | disclosed |
| US-20250270207-A1 | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE | UNIVERSITE DE MONTREAL (CA) | 2025-08-28 | — | — | US | disclosed |
| EP-3707126-B1 | IRE1 SMALL MOLECULE INHIBITORS | UNIV CORNELL (US) | 2025-05-14 | — | — | EP | disclosed |
| CN-119661409-A | Preparation of 1, 4-sulfonyl chloride compound by visible light-induced free radical reaction | 浙江师范大学 | 2025-03-21 | — | — | CN | disclosed |
| US-20240425477-A1 | IRE1 SMALL MOLECULE INHIBITORS | CORNELL UNIVERSITY | 2024-12-26 | — | — | US | disclosed |
| US-12139488-B2 | Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease | Université de Montréal (CA) | 2024-11-12 | — | — | US | disclosed |
| WO-2024215130-A1 | NOVEL GSPT1 DEGRADER AND USE THEREOF | CYRUS THERAPEUTICS INC. (KR) | 2024-10-17 | — | — | WO | disclosed |
| US-7507733-B2 | 11b-HSD1 inhibitors for the treatment of diabetes | HOFFMANN-LA ROCHE INC. (US) | 2009-03-24 | — | — | US | disclosed |
| US-20080200495-A1 | Pyrrolopyridine Compounds, Method of Making Them and Uses Thereof | LABORATOIRES FOURNIER S.A. (FR) | 2008-08-21 | — | — | US | disclosed |
| CN-101242833-A | Pyrrolopyridine derivatives and use of same as PPAR receptor modulators | FOURNIER LAB SA (FR) | 2008-08-13 | — | — | CN | disclosed |
| CN-1972918-A | Pyrimidine derivatives | HOFFMANN LA ROCHE (CH) | 2007-05-30 | — | — | CN | disclosed |
| EP-1763517-A2 | PYRIMIDINE DERIVATIVES AS 11BETA-HSD1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-03-21 | — | — | EP | disclosed |
| CN-1249039-C | Inhibitors of 11 beta-hydroxysteroid dehydrogenase type I | BIOVITRUM AB (SE) | 2006-04-05 | — | — | CN | disclosed |
| WO-2006000371-A2 | PYRIMIDINE DERIVATIVES AS 11BETA-HSD1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-01-05 | — | — | WO | disclosed |
| US-20050288308-A1 | 11B-HSD1 inhibitors for the treatment of diabetes | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-29 | — | — | US | disclosed |
| CN-1438997-A | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type I | BIOVITRUM AB (SE) | 2003-08-27 | — | — | CN | disclosed |
| EP-0326170-A1 | Sulfonamide and herbicide containing the same as active ingredient | MITSUBISHI KASEI CORPORATION (JP) | 1989-08-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250270207-A1 | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE | BRAF, NRAS, KRAS | ALDH1A1 1636/4885RXFP1 3104/4885L3MBTL1 2916/4885 |
| US-20240425477-A1 | IRE1 SMALL MOLECULE INHIBITORS | XBP1, ERN2, ERN1 | ALDH1A1 3482/4885RXFP1 4288/4885L3MBTL1 446/4885 |
| US-20050288308-A1 | 11B-HSD1 inhibitors for the treatment of diabetes | HSD11B1, HSD17B1, HSD3B1 | ALDH1A1 82/4885RXFP1 976/4885L3MBTL1 4091/4885 |
| US-12139488-B2 | Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease | BRAF, NRAS, KRAS | ALDH1A1 1636/4885RXFP1 3104/4885L3MBTL1 2916/4885 |
| US-20080200495-A1 | Pyrrolopyridine Compounds, Method of Making Them and Uses Thereof | LIPG, PCSK9, PNLIP | ALDH1A1 1350/4885RXFP1 4005/4885L3MBTL1 4812/4885 |
| US-12479818-B2 | Treatment of fibrosis with IRE1 small molecule inhibitors | XBP1, DDIT3, HSP90B1 | ALDH1A1 2568/4885RXFP1 1165/4885L3MBTL1 1288/4885 |
| US-12479842-B2 | Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease | BRAF, NRAS, DPYD | ALDH1A1 1619/4885RXFP1 3082/4885L3MBTL1 2973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.